Central Drugs Standard Control Organization

What Central Drugs Standard Control Organization does

The Central Drugs Standard Control Organisation (CDSCO) is India's National Regulatory Authority (NRA) for drugs, cosmetics, biologics, medical devices, diagnostics, and clinical trials, operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Established under the Drugs and Cosmetics Act, 1940 and headquartered at FDA Bhawan, Kotla Road, New Delhi, CDSCO holds statutory authority over drug approvals, clinical trial oversight, manufacturing license approvals, import registration, standards setting, and post-marketing surveillance for a pharmaceutical market valued at $50 billion that supplies approximately 20% of the world's generic medicines and 60% of its vaccines to over 200 countries.

CDSCO operates a portfolio of interconnected digital platforms, including the SUGAM portal for drug approvals, the Online System for Medical Devices, the State Drugs Licensing System, the Online National Drug Licensing System (ONDLS) for WHO GMP certifications, e-RaktKosh for blood bank oversight, and the in-development Digital Drugs Regulatory System (DDRS) that will integrate 21 national databases. Physical infrastructure comprises 6 zonal offices, 4 sub-zonal offices, 13 port offices, and 7 Central/Regional Drugs Testing Laboratories (CDL, CDTL, RDTL), plus the Indian Pharmacopoeia Commission (IPC) and National Institute of Biologicals (NIB). The organization is funded by government budgetary allocations and collects statutory fees for regulatory services under fee schedules defined in the Drugs Rules, 1945. Key recent actions include the India-Brazil ANVISA MoU, a staffing overhaul targeting 1,500+ new scientists, and expanded QR code-based track-and-trace mandates across vaccines, antimicrobials, anti-cancer drugs, and narcotic substances.

Name

Central Drugs Standard Control Organization

Legal name

Central Drugs Standard Control Organisation

Website

https://cdsco.gov.in

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

India's National Regulatory Authority for drugs, cosmetics, biologics, medical devices, and clinical trials under the Ministry of Health & Family Welfare, regulating the $50 billion Indian pharmaceutical market through digital platforms including SUGAM, ONDLS, and the in-development DDRS, supported by 6 zonal offices and 7 testing laboratories nationwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

Keywords

• Pharmaceutical regulatory services
• Drug approval licensing
• Clinical trial oversight
• Medical device regulation
• Pharmacovigilance monitoring

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Regulatory Fee Collection: CDSCO collects fees for drug approvals, clinical trial permissions, import licenses, and manufacturing licenses. The organization also processes fees for Certificates of Pharmaceutical Products, BA/BE studies, and medical device registrations through its online portals SUGAM and CDSCO Online.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

CDSCO is India's National Regulatory Authority (NRA) that regulates drugs, cosmetics, medical devices, biologics, vaccines, blood products, and clinical trials under the Drugs and Cosmetics Act, 1940. The organization provides regulatory services including drug approvals, clinical trial permissions, import licensing, manufacturing license approvals, and post-marketing surveillance through the Pharmacovigilance Programme of India (PvPI). It coordinates with 47 state drug regulatory authorities for uniform enforcement across India.

Product overview

CDSCO operates as India's apex drug regulatory authority under the Directorate General of Health Services, Ministry of Health & Family Welfare. It functions as a platform organization providing regulatory oversight through multiple interconnected digital systems including the SUGAM Portal for central drug approvals, Online System for Medical Devices for device regulation, State Drugs Licensing System for state coordination, and the Online National Drug Licensing System (ONDLS) for GMP certifications. The organization maintains a nationwide infrastructure of six zonal offices, four sub-zonal offices, thirteen port offices, and seven Central Drug Testing Laboratories (CDL/CDTL/RDTL). CDSCO's regulatory scope covers drugs, cosmetics, medical devices, biologics, vaccines, blood products, clinical trials, and Ayush products under the Drugs and Cosmetics Act 1940, Drugs Rules 1945, Medical Devices Rules 2017, New Drugs and Clinical Trials Rules 2019, and Cosmetics Rules 2020. The organization is undergoing digital transformation with development of the Digital Drugs Regulatory System (DDRS) to unify all regulatory functions into a single interoperable platform integrating with 21 national databases.

Differentiator

Problem solved

Functional benefit

Products and services

• SUGAM Portal CDSCO's primary online portal for drug licensing, import registration, and regulatory approvals. Enables pharmaceutical companies to submit applications, track status, and receive approvals for drugs and cosmetics. Used by pharmaceutical manufacturers, importers, and clinical trial sponsors.
• Online System for Medical Devices Dedicated online portal for regulatory submissions and approvals related to medical devices, enabling manufacturers to import, register, and obtain licenses for medical devices in India under the Medical Devices Rules, 2017.
• State Drugs Licensing System Digital platform for state-level drug licensing, enabling coordination between central and state drug regulatory authorities for unified drug regulation across India's 28 states and 8 Union Territories.
• Online National Drug Licensing System (ONDLS) Portal for issuing Certificates of Pharmaceutical Products under WHO's Good Manufacturing Practices scheme and managing drug licensing across states. Now also used for digital tracking of high-risk solvents in pharmaceutical manufacturing.
• Drug Testing Laboratories Network of Central Drug Testing Laboratories including CDL Kasauli, CDL Kolkata, CDTL Chennai, CDTL Hyderabad, CDTL Mumbai, RDTL Chandigarh, and RDTL Guwahati for quality testing of drugs and cosmetics in India.
• Pharmacovigilance Programme of India (PvPI) Post-marketing surveillance programme for monitoring adverse drug reactions and ensuring drug safety across India's pharmaceutical market. Tracks safety signals from marketed drugs and coordinates with WHO global pharmacovigilance.
• Clinical Trial Regulation Services Regulatory oversight for clinical trials in India including ethics committee approvals, global clinical trial authorizations, and serious adverse event reporting under New Drugs and Clinical Trials Rules, 2019.
• BA/BE Services Bioavailability and bioequivalence services and regulatory framework for generic drug approvals ensuring therapeutic equivalence to reference products in India.

Named customers8 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Indian Council of Medical Research (ICMR)coreStrategic or Co-development Partner · 11 June 2026ICMR launched MedTech Mitra portal under NITI Aayog guidance providing regulatory facilitation from CDSCO for MedTech innovators. ICMR-National Medical Commission medical thesis repository (Medical Shodhganga) and health data repositories developed with CDSCO support.
• Brazil's Health Regulatory Agency (ANVISA)coreStrategic or Co-development Partner · 22 February 2026India and Brazil exchanged a Memorandum of Understanding between CDSCO and ANVISA establishing a structured framework for cooperation in pharmaceutical and medical product regulation including drugs, biological products, and medical devices. Signed in presence of PM Narendra Modi and President Lula, aims to promote regulatory convergence, strengthen supply chains, and facilitate access to affordable healthcare.
• Centre for Development of Advanced Computing (C-DAC)coreTechnology or IntegrationC-DAC designed, developed, and maintains CDSCO's official website and digital platforms including SUGAM portal and Online National Drug Licensing System in coordination with CDSCO and state drug regulatory authorities.
• National Pharmaceutical Pricing Authority (NPPA)coreStrategic or Co-development PartnerNPPA coordinates with CDSCO on drug pricing, including one-time ceiling price increases for critical cancer medicines like Carboplatin and Cisplatin injections, and approvals for essential medicine pricing adjustments.
• VietnamminorStrategic or Co-development PartnerIndia-Vietnam Enhanced Comprehensive Strategic Partnership includes pharmaceutical cooperation agreements during Vietnamese President To Lam's state visit to New Delhi, targeting USD 25 billion bilateral trade by 2030.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO provides routine global pharmacovigilance support, issued alerts on substandard cough syrups (Coldrif, Respifresh TR, ReLife), and seeks details from Indian government on drug export quality issues. WHO GMP certification handled through CDSCO's ONDLS system.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Others

• National Institute of Biologicals (NIB), India: NIB is an Indian government institute under CDSCO's parent Ministry that tests and releases biologicals including vaccines. While not a regulator itself, it is a closely-adjacent quality-testing arm to CDSCO's drug testing laboratory network (CDL/CDTL/RDTL), often involved in batch release decisions for the same biologics CDSCO approves.
• WHO Prequalification Programme: WHO Prequalification is not a national regulator but evaluates medicines, vaccines, and diagnostics for UN procurement agencies — and CDSCO's ONDLS directly issues Certificates of Pharmaceutical Products supporting WHO GMP status. It functions as the international quality overlay to which CDSCO aligns its regulatory outputs.

Direct peers

• China National Medical Products Administration (NMPA): NMPA is China's national drug and medical device regulator with comparable scope — new drug approvals, clinical trial oversight, and post-market surveillance. As the regulator for the world's largest pharma producer by volume alongside India, NMPA is CDSCO's primary peer in regulating API and generic drug manufacturing for global export markets.
• Health Canada: Health Canada's Therapeutic Products Directorate oversees drug and device regulation similar to CDSCO. Both agencies engage in international pharmacovigilance, recognize WHO GMP standards, and increasingly coordinate on AI medical device frameworks relevant to global pharma supply chains.
• Japan Pharmaceuticals and Medical Devices Agency (PMDA): PMDA is Japan's national drug and medical device regulator with rigorous scientific review standards. Comparable function in new drug approvals, medical device classification (including Class C categories similar to CDSCO's recent AI device classification), and pharmacovigilance for a major Asian pharma market.
• U.S. Food and Drug Administration (FDA): The FDA is the U.S. national drug and medical device regulator — the most globally influential comparator to CDSCO. Both agencies approve new drugs, oversee clinical trials, regulate medical devices, and issue safety alerts; CDSCO's recent digital modernization (DDRS, SUGAM) and AI device frameworks explicitly track FDA precedent.
• Brazil's Health Regulatory Agency (ANVISA): ANVISA is Brazil's national drug and health product regulator and signed a bilateral convergence MoU with CDSCO in February 2026. Comparable mandate covering drug approvals, biologics, and medical devices across a large emerging-market pharmaceutical industry serving global generics supply.
• UK Medicines and Healthcare products Regulatory Agency (MHRA): MHRA is the UK's standalone drug and medical device regulator post-Brexit, with similar structure to CDSCO as a national authority outside a larger supranational framework. Both agencies emphasize post-Brexit/post-liberalization independent approval pathways and WHO GMP cooperation.
• Australia's Therapeutic Goods Administration (TGA): TGA is Australia's national regulator for therapeutic goods including medicines, medical devices, and biologics. Comparable scope in approval pathways, GMP inspections, and post-market surveillance; TGA's reliance recognition arrangements provide a model CDSCO explores through its WHO GMP/ONDLS framework.

Regional players

• European Medicines Agency (EMA): EMA serves as the central drug regulator for the European Union, coordinating approvals across member states — structurally analogous to CDSCO's mandate to unify enforcement across India's 28 states. EMA's centralized scientific evaluation and pharmacovigilance framework is a benchmark CDSCO references in its digital convergence initiatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/central-drugs-testing-laboratory

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Central Drugs Standard Control Organization